Table 4.

Changes in Gastrointestinal Symptom Scores From Baseline at Week 2

GIS	Mosapride citrate SR group	Mosapride citrate CR group	P-value
PPS	n = 51	n = 49
Baseline	13.55 ± 5.21	13.84 ± 5.32	0.721b
Week 2	6.76 ± 6.09	4.67 ± 3.69
Changea	–6.78 ± 5.32	–9.16 ± 5.13	0.059b
In group P-value	< 0.001c	< 0.001d
FAS	n = 57	n = 57
Baseline	13.55 ± 5.00	14.07 ± 5.58	0.541b
Week 2	6.66 ± 5.91	5.33 ± 5.38
Changea	–6.66 ± 5.20	–8.74 ± 5.66	0.055b
In group P-value	< 0.001c	< 0.001d

GIS, gastrointestinal symptom scores; PPS, per-protocol set; FAS, full analysis set.

^aChanges in score related to symptoms (week 2-baseline).

^bWilcoxon rank sum test.

^cPaired t test.

^dWilcoxon signed rank test.